SCHEMBL4866490

SCHEMBL4866490

C[C@H]1CN(CC(=O)NCc2cc(F)ccc2F)CCN1C[C@@H](O)COc1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
TDP1 Q9NUW8 1/20 0.41
CYP3A4 P08684 2/20 0.41
TSHR P16473 2/20 0.41
CYP2D6 P10635 1/20 0.41
NFKB1 P19838 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
ADRA1A P35348 1/20 0.41
DRD3 P35462 1/20 0.41
HTR2B P41595 1/20 0.41
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4858682 0.93 KMT2A (0.52) KMT2AMEN1TDP1CYP3A4TSHR
SCHEMBL4859676 0.93 KMT2A (0.55) KMT2AMEN1TDP1CYP3A4TSHR
SCHEMBL4861676 0.89 KMT2A (0.51) KMT2AMEN1CYP3A4TSHRCYP2D6
SCHEMBL4866039 0.89 MEN1 (0.53) KMT2AMEN1CYP3A4TSHRCYP2D6
SCHEMBL4865355 0.89 KMT2A (0.60) KMT2AMEN1TDP1CYP3A4TSHR
SCHEMBL4865219 0.89 MEN1 (0.56) KMT2AMEN1CYP3A4TSHRCYP2D6
SCHEMBL4862091 0.89 MEN1 (0.49) KMT2AMEN1CYP2D6CCR1
SCHEMBL4866603 0.89 MEN1 (0.52) KMT2AMEN1CYP3A4TSHRCYP2D6
SCHEMBL4864114 0.87 MEN1 (0.52) KMT2AMEN1CYP2D6KCNH2ALDH1A1
SCHEMBL4859600 0.87 MEN1 (0.56) KMT2AMEN1CYP3A4TSHRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A KMT2A 3201/4885MEN1 3200/4885TDP1 3448/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A KMT2A 3029/4885MEN1 2899/4885TDP1 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.